Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms

British Journal of Cancer

Volumn 95, Issue 10, 2006, Pages 1424-1431

  Walker, C ^a   Haylock, B ^b   Husband, D ^b   Joyce, K A ^a   Fildes, D ^a   Jenkinson, M D ^c,d   Smith, T ^c   Broome, J ^c   Kopitzki, K ^d   Du Plessis, D G ^d   Prosser, J ^e   Vinjamuri, S ^e   Warnke, P C ^d  

^a CLATTERBRIDGE HOSPITAL   (United Kingdom)

^b CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^c WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

1p 19q loss; 18Fluorodeoxyglucose SPECT; 201Thallium SPECT; Chemosensitivity; Oligodendroglioma

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; THALLIUM 201; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; GENOTYPE; HUMAN; LOG RANK TEST; MALE; MULTIVARIATE ANALYSIS; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOMUSTINE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; PROCARBAZINE; PROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VINCRISTINE;

EID: 33751024541     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603390     Document Type: Article

References (41)

1. Benard F, Romsa J, Hustinx R (2003) Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med 33: 148-162
2. Brock CS, Young H, O'Reilly SM, Matthews J, Osman S, Evans H, Newlands ES, Price PM (2000) Early evaluation of tumour metabolic response using (18F)fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 82: 608-615
3. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90: 1473-1479
4. Castilla EA, Prayson RA, Kanner AA, Rybicki LA, Tubbs RR, Vogelbaum MA, Barnett GH (2003) Cyclooxygenase-2 in oligodendroglial neoplasms. Cancer 98: 1465-1472
5. Comte F, Bauchet L, Rigau V, Hauet JR, Fabbro M, Coubes P, Chevalier J, Mariano-Goulart D, Rossi M, Zanca M (2006) Correlation of preoperative thallium SPECT with histological grading and overall survival in adult gliomas. Nucl Med Commun 27: 137-142
6. Datta NR, Pasricha R, Gambhir S, Prasad SN, Phadke RV (2004) Comparative evaluation of 201Tl SPECT and CT in the follow-up of irradiated brain tumors. Int J Clin Oncol 9: 51-58
7. Engelhard HH, Stelea A, Mundt A (2003) Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 60: 443-456
8. Giammarile F, Cinotti LE, Jouvet A, Ramackers JM, Saint Pierre G, Thiesse P, Jouanneau E, Guyotat J, Pelissou-Guyotat I, Setiey A, Honnorat J, Le Bars D, Frappaz D (2004) High and low grade oligodendrogliomas (ODG): correlation of amino-acid and glucose uptakes using PET and histological classifications. J Neurooncol 68: 263-274
9. Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S, Graeber MB, Bauserman S, Buckner JC, Burton J, Riepe R, Tazelaar HD, Nascimento AG, Crotty T, Keeney GL, Pernicone P, Altermatt H (2001) Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 60: 248-262
10. Hartmann C, Mueller W, von Deimling A (2004) Pathology and molecular genetics of oligodendroglial tumors. J Mol Med 82: 638-655
11. Herholz K, Pietrzyk U, Voges J, Schroder R, Halber M, Treuer H, Sturm V, Heiss WD (1993) Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 79: 853-858
12. Higa T, Maetani S, Yoichiro K, Nabeshima S (2001) TI-201 SPECT compared with histopathologic grade in the prognostic assessment of cerebral gliomas. Clin Nucl Med 26: 119-124
13. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Criniere E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broet P, Sanson M, Delattre JY (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22: 3133-3138
14. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN (2001) Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7: 839-845
15. Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M, Yarosh DB, Bearman SI, Giroux DJ, Schold SC (1998) Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 16: 3310-3315
16. Jager HR, Waldman AD, Benton C, Fox N, Rees J (2005) Differential Chemosensitivity of Tumor Components in a Malignant Oligodendroglioma: Assessment with Diffusion-Weighted, Perfusion-Weighted, and Serial Volumetric MR Imaging. AJNR Am J Neuroradiol 26: 274-278
17. Jenkinson MD, Smith TS, Joyce K, Fildes D, du Plessis DG, Warnke PC, Walker C (2005) MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology 64: 2085-2089
18. Jeuken JW, von Deimling A, Wesseling P (2004) Molecular pathogenesis of oligodendroglial tumors. J Neurooncol 70: 161-181
19. Kleihues P, Cavanee W (2000) Pathology and genetics of tumors of the nervous system. In: Kleihues P, Cavanee WK (eds). Lyon: IARC Press
20. Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, Wilson CB (1980) Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64: 237-244
21. Levivier M, Wikler Jr D, Massager N, David P, Devriendt D, Lorenzoni J, Pirotte B, Desmedt F, Simon Jr S, Goldman S, Van Houtte P, Brotchi J (2002) The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review. J Neurosurg 97: 542-550
22. Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280
23. Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, Christian B, Ruppert J, Bernstein T, Kraus G, Mantil JC (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64: 227-237
24. Pardo FS, Aronen HJ, Fitzek M, Kennedy DN, Efird J, Rosen BR, Fischman AJ (2004) Correlation of FDG-PET interpretation with survival in a cohort of glioma patients. Anticancer Res 24: 2359-2365
25. Perry JR, Cairncross JG (2003) Glioma Therapies: How to Tell Which Work? J Clin Oncol 21: 3547-5349
26. Prados MD (2000) Systemic Chemotherapy. In: Bernstein M, Berger M (eds) Neuro-Oncology. Thieme: Verlag, pp 226-233
27. Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62: 111-126
28. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18: 636-645
29. Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ (2005) Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103: 802-809
30. Stokkel M, Stevens H, Taphoorn M, Van Rijk P (1999) Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201Tl SPET versus 18F-FDG PET using a dual-headed coincidence camera-a pilot study. Nucl Med Commun 20: 411-417
31. van den Bent MJ (2004) Diagnosis and management of oligodendroglioma. Semin Oncol 31: 645-652
32. van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97: 1276-1284
33. Vos MJ, Hoekstra OS, Barkhof F, Berkhof J, Heimans JJ, Van Groeningen CJ, Vandertop WP, Slotman BJ, Postma TJ (2003) Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. J Clin Oncol 21: 3559-3565
34. Walker C, du Plessis DG, Fildes D, Haylock B, Husband D, Jenkinson MD, Joyce KA, Broome J, Kopitski K, Prosser J, Smith T, Vinjamuri S, Warnke PC (2004) Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 10: 7182-7191
35. Walker C, du Plessis DG, Joyce KA, Fildes D, Gee A, Haylock B, Husband D, Smith T, Broome J, Warnke PC (2005) Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann Neurol 57: 855-865
36. Walker C, du Plessis DG, Joyce KA, Machell Y, Thomson-Hehir J, Al Haddad SA, Broome JC, Warnke PC (2003) Phenotype versus genotype in gliomas displaying inter- or intratumoral histological heterogeneity. Clin Cancer Res 9: 4841-4851
37. Walker C, Haylock B, Husband D, Joyce KA, Fildes D, Jenkinson MD, Smith T, Broome J, du Plessis DG, Warnke PC (2006) Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology 66: 1661-1667
38. Warnke PC (1998) Physiological characterization of malignant oligodendrogliomas responding to PCV chemotherapy. J Neurosurg 88: 399A
39. Warnke PC, Kopitzki K, Ostertag CB, Vinjamuri S (2003) The role of functional imaging in brain tumours. World J Nucl Med 2: 37-44
40. Warnke PC, Timmer J, Ostertag CB, Kopitzki K (2005) Capillary physiology and drug delivery in central nervous system lymphomas. Ann Neurol 57: 136-139
41. White ML, Zhang Y, Kirby P, Ryken TC (2005) Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol 26: 784-790